telmisartan + metformin

Telmisartan + metformin is a fixed-dose combination of two small molecule drugs used primarily for the management of patients with both type 2 diabetes mellitus and hypertension or metabolic syndrome. Telmisartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II on its receptor, leading to vasodilation and reduced aldosterone secretion. Metformin is a biguanide antihyperglycemic agent that decreases hepatic glucose production, increases insulin sensitivity, and enhances peripheral glucose uptake. The combination targets both hyperglycemia and hypertension, offering potential cardiovascular protective effects through mechanisms such as activation of AMP-activated protein kinase (AMPK), improvement in endothelial function, reduction in oxidative stress, and modulation of metabolic pathways involved in insulin resistance[3][5][6]. This dual therapy may also help reverse features of metabolic syndrome including weight gain, hepatic steatosis, adipocyte hypertrophy, and insulin resistance[6].